Vanquish Oncology, Inc. announces multimillion dollar investment to move PAC-1 to human clinical trials for cancer patients.

Cancer drug tested in pet dogs is now bound for human trials. University of Illinois chemistry professor Paul Hergenrother, left, and veterinary clinical medicine professor Tim Fan led a study of an anti-cancer compound in pet dogs that is now headed for human clinical trials.

Continue reading the Illinois News Bureau article.